anti-LMO1 (LMO1) 抗体产品概述

在www.antibodies-online.cn可供21 LIM Domain Only 1 (LMO1) 抗体的4不同的供货商。 总共22 LMO1产品已列进来了。
列出全部抗体 基因 基因ID UniProt
LMO1 245979  
LMO1 13162 Q61327
LMO1 6531 Q01959

最受欢迎的抗anti-LMO1 (LMO1) 抗体

抗Rat (Rattus) LMO1 抗体:

抗Mouse (Murine) LMO1 抗体:

抗Human LMO1 抗体:

所有可销售的anti-LMO1 抗体



Mouse (Murine) LIM Domain Only 1 (LMO1) interaction partners

  1. These behavioral and molecular phenotypes indicate that a genetic-driven DAT (显示 SLC6A3 抗体) hypofunction alters neurodevelopmental trajectories consistent with ADHD, but not with schizophrenia and bipolar disorders.

  2. An exquisite microanatomical regulation of dopamine by the dopamine transporter was identified in striosomes relative to the matrix in the corpus striatum.

  3. Data suggest that environment pollutants methylmercury and 1-methyl-4-phenylpyridinium decrease release of dopamine from dopaminergic neurons; this mechanism involves down-regulation of expression of Slc6a3 (显示 SLC6A3 抗体).

  4. This study show that Dopamine transporter is enriched in filopodia and induces filopodia formation.

  5. The sigma-1R deficiency through suppressing NR2B (显示 GRIN2B 抗体) function and DAT (显示 SLC6A3 抗体) expression can reduce MPTP (显示 PTPN2 抗体)-induced death of dopaminergic neurons and parkinsonism.

  6. DAT (显示 SLC6A3 抗体) gene knockout in mice results dendritic spine loss in pyramidal neurons in the CA1 (显示 CA1 抗体) field of the hippocampus.

  7. Results show that moderate increases in DAT (显示 SLC6A3 抗体) function cause spontaneous dopaminergic cell loss, oxidative stress and fine motor impairment that is reversed by l-DOPA treatment

  8. Chronic and acute reductions of DAT (显示 SLC6A3 抗体) functioning in mice impaired decision-making.

  9. These results demonstrate that the presence of the N-terminal tag leads to impaired DAT (显示 SLC6A3 抗体) protein expression in vivo due in part to improper trafficking of the tagged transporter.

  10. studies demonstrate an in vivo functional impact of the DAT (显示 SLC6A3 抗体) Val559 variant, providing support for the ability of DAT (显示 SLC6A3 抗体) dysfunction to impact risk for mental illness.

Human LIM Domain Only 1 (LMO1) interaction partners

  1. Allosteric modulation of human dopamine transporter activity under conditions promoting its dimerization

  2. A combined haplotype (9R-A2) of DAT-1 (显示 SLC6A3 抗体) and DRD2 (显示 DRD2 抗体) genes was associated with the murderer phenotype among Pakistani violent criminal inmates.

  3. SLC6A3 gene may have a role in susceptibility to late-onset alcohol dependence in the Han Chinese population.

  4. This result suggests that persistent drug-induced parkinsonism in patients with visually normal DAT (显示 SLC6A3 抗体) imaging may be associated with subtle decrement of DAT (显示 SLC6A3 抗体) activity.

  5. the dopamine transporter SLC6A3 constitutes a novel biomarker that is highly specific for clear cell renal cell carcinoma

  6. Data suggest that variants rs28363170 and rs3836790 in the solute carrier family 6 member 3 gene are not associated with sporadic Parkinson's disease in Han Chinese population.

  7. Study systematically designed and characterized a set of 24 substrate-based bivalent ligands, and in combination with mutagenesis, induced-fit docking calculations, electrophysiology, and cysteine accessibility measurements; revealed novel insight into the molecular basis of substrate recognition in hSERT (显示 SLC6A4 抗体) and hDAT

  8. these findings provide compelling experimental evidence that DAT (显示 SLC6A3 抗体) N and C termini synergistically contribute to substrate and inhibitor affinities.

  9. these results are the first demonstration of pharmacological chaperoning of DAT (显示 SLC6A3 抗体) and suggest this may be a viable approach to increase DAT (显示 SLC6A3 抗体) levels in Dopamine Transporter Deficiency Syndrome and other conditions associated with reduced DAT (显示 SLC6A3 抗体) function.

  10. total of 1799 differentially methylated regions were identified including SLC6A3, Rab40C, ZNF584, and FOXD3 whose significant methylation differences were confirmed in breast cancer patients through quantitative real-time polymerase chain reaction.Methylation of those aforementioned genes in white blood cells of our young patients may highlight their potential as early epimarkers

LMO1 抗原简介

Antigen Summary

This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.

Alternative names and synonyms associated with LMO1

  • LIM domain only 1 (Lmo1) 抗体
  • solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 (Slc6a3) 抗体
  • solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) 抗体
  • solute carrier family 6 (neurotransmitter transporter), member 3 (Slc6a3) 抗体
  • DAT 抗体
  • DAT1 抗体
  • Lmo3 抗体
  • PKDYS 抗体

Protein level used designations for anti-LIM Domain Only 1 (LMO1) 抗体

LIM domain only protein 3 , LMO-3 , LIM domain only 3 , neuronal-specific transcription factor DAT1 , dopamine-inducible LIM-domain transcription factor DAT1 , DA transporter , dopamine transporter 1 , sodium-dependent dopamine transporter , solute carrier family 6 member 3 , solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 , DAT , solute carrier family 6, member 3

245979 Rattus norvegicus
13162 Mus musculus
6531 Homo sapiens
24898 Rattus norvegicus
anti-LMO1 (LMO1) 抗体 精选生产商